Gabriele Bergers, PhD

University of Munich, Germany, B.S., 1988, Biochemistry
Max Planck Institute (MPI), Martinsried, Germany, M.S., 1989, Biochemistry/Virology
Institute for Molecular Pathology (IMP), University of Vienna, Austria, Ph.D., 1993, Molecular Biology/Genetics
University of California, San Francisco, Postdoctoral Fellow, 1994-1997, Cancer Biology

• 1999-2001
  Assistant Research Biochemist, Department of Biochemistry and Biophysics, UCSF
• 2001-2005
  Assistant Professor, Brain Tumor Research Center and Departments of Neurosurgery, UCSF
• 2005-2011
  Associate Professor, Brain Tumor Research Center and Departments of Neurosurgery and Anatomy, UCSF
• 2011-present
  Professor, Brain Tumor Research Center and Departments of Neurosurgery and Anatomy, UCSF

• 2002-2002
  American Cancer Society Award
• 2003-2002
  V Foundation Scholar Award
• 2002-2004
  Sydney Kimmel Scholar Award
• 2004-2005
  Goldhirsh Foundation Award
• 2005-2006
  Sandler Opportunity Award
• 2005-Present
  Neill H. and Linda S. Brownstein Endowed Chair in Brain Tumor Research

• Bergers G., Javaherian K., Lo K.M., Folkman J., Hanahan D. (1999): Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284(5415):808-12.
• Bergers G., Brekken R., McMahon G., Vu T.H., Itoh T., Tamaki K., Tanzawa K., Thorpe P., Itohara S., Werb Z. and Hanahan D. (2000): Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nature Cell Biol. 2: 737-744.
• Bergers G., Song S., Meyer-Morse N., Bergsland E. and D. Hanahan (2003):.Benefits of targeting both pericytes and endothelial cells in the tumor vasculature. J Clin. Invest 111: 1287-1295.
• Blouw B., Song H., Tihan T., Bosze J., Ferrara N., Gerber H.-P., Johnson R.S. and Bergers G. (2003): The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell 4: 133-46.
• Bergers G. and Benjamin L.E. (2003): Tumorigenesis and the Angiogenic Switch, Nature Rev Cancer 3: 401-410.
• Kanamori M, VandenBerg SR, Bergers G, Berger MS, Pieper RO(2004): Integrin beta3 overexpression suppresses tumor growth in a human model of gliomagenesis: implications for the role of beta3 overexpression in glioblastoma multiforme." Cancer Res. 64(8): 2751-8.
• Berger M., Bergers G., Arnold B., Haemmerling G.J. and Ganss R. (2005): “Regulator of G protein signaling-5 induction in pericytes coincides with active vessel remodeling during neovascularization”. Blood 105: 1094-1101.
• Song S, Ewald AJ, Stallcup W, Werb Z, Bergers G. (2005). “PDGFRbeta(+) perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival”. Nature Cell Biol. 9: 870-879.
• Bergers, G., Song S (2005). “The role of pericytes in blood-vessel formation and maintenance”. Neuro-Oncol. 7:452-64.
• Casanovas O, Hicklin, D, Bergers G and Hanahan D. (2005).“Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late stage pancreatic islet tumors”. Cancer Cell 8:299-309.
• Kawaguchi, T., Yamashita, Y, Kanamori, M., Endersby R., Bankiewicz, K.S., Baker, S.J., Bergers, G. and Russ, P. (2006). The PTEN/Akt pathway dictates the direct alphaVbeta3-dependent growth-inhibitory action of an active fragment of tumstatin in glioma cells in vitro and in vivo. Cancer Res. 23:11331-40.
• Du R., Petritsch C., GanssR., VandenBerg S. and Bergers G (2007). “Matrix Metalloproteinase-2 regulates vascular patterning and growth affecting tumor cell survival and invasion.” Neuro-Oncol. 10:254-64.
• Chesler L, Goldenberg DD, Seales IT, Satchi-Fainaro R, Grimmer M, Collins R, Struett C, Nguyen KN, Kim G, Tihan T, Bao Y, Brekken RA, Bergers G, Folkman J, Weiss WA (2007). Malignant progression and blockade of angiogenesis in a murine transgenic model of neuroblastoma. Cancer Res 67:9435-42.
• Du, R, Lu, K., Petritsch, C, Liu, P., Ganss, R.,Passegue, E., Song, H., Johnson, R.S, Werb, Z and Bergers, G. (2008). HIF-1a induces recruitment of bone marrow-derived vascular modulatory cells to regulate angiogenesis and invasion in tumors. Cancer Cell13: 206-20.
• Silber J, Lim DA, Petritsch C, Persson AI, Maunakea AK, Yu M, Vandenberg SR, Ginzinger DG, James CD, Costello JF, Bergers G, Weiss WA, Alvarez-Buylla A, Hodgson JG. (2008). miR-124 and miR-137 inhibit proliferation of glioblastoma `multiforme cells and induce differentiation of brain tumor stem cells. BMC Med 6:14.
• Bergers, G. and Hanahan, D. (2008) Modes of antiangiogenic resistance. Nat Rev Cancer 8, 592-603.
• Lu, KV.,Lamagna, C. and Bergers, G. (2008). Vascular Progenitors and Proangiogenic Monocytes in Tumor Angiogenesis. Methods Enzymol. 445: 53-82.
• Lu KV, Zhu S, Cvrljevic A, Huang TT, Sarkaria S, Ahkavan D, Dang J, Dinca EB, Plaisier SB, Oderberg I, Lee Y, Chen Z, Caldwell JS, Xie Y, Loo JA, Seligson D, Chakravari A, Lee FY, Weinmann R, Cloughesy TF, Nelson SF, Bergers G, Graeber T, Furnari FB, James CD, Cavenee WK, Johns TG, Mischel PS (2009). Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients. Cancer Res. 69, 6889-98.
• Pàez-Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, T., Viñals, F., Inoue, M., Bergers, G., Hanahan, D. and Casanovas D. (2009). Anti-angiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15: 220-231.
• Bergers, G. (2009). GBM neovascularization: Functional significance of bone marrow derived cells and evasive mechanisms to antiangiogenic therapy. In: CNS Cancer, Models, Prognostic Factors, Targets and Therapeutic Approaches. (van Meir E eds.) Humana Press (Springer).
• Persson, AI, Petritsch, C, Swartling FJ, Itsara, M, Sim, FJ, Auvergne, RM, Goldenberg, DD, Vandenberg, SR, Nguyen, KN, Yakovenko, S, Ayers-Ringler, J, Nishiyama, A, Stallcup, WB, Berger, MS, Bergers, G, McKnight, TR, Goldman, SA, Weiss, WA. (2010). Non-stem cell origin of oligodendroglioma. Cancer Cell 18 :669-82.
• Sugiarto, S, Persson, AI, Gonzalez-Munoz E, Waldhuber, M, Lamagna, C, Andor, N, Hanecker, P, Ayer Ringler J, Phillips, J, Siu, L, Lim, D, Vandenberg, S; Stallcup, W, Berger M,S, Bergers, G, Weiss, WA, Petritsch, C. (2011). Asymmetry-defective oligodendrocyte progenitors are glioma precursors. Cancer Cell 20:328-40.
• Lu, KV.,Chang, J., Meyronet, D., Pandika, M., Aghi, M., Meyronet, D , Isachenko N., Fouse, SD., Phillips, J., Cheresh, D. and Bergers, G. VEGF inhibits tumor cell invasion through a novel c-Met/VEGFR2 complex (in revision at Cancer Cell).